Forimtamig for Multiple Myeloma
Recruiting at 37 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Hoffmann-La Roche
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called Forimtamig on patients with a type of cancer called multiple myeloma. These patients have no other treatment options or cannot tolerate existing treatments. The drug aims to either kill the cancer cells or help the immune system fight them.
Research Team
CT
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with relapsed or refractory Multiple Myeloma who've tried other treatments like IMiDs and PIs but can't use them anymore. They should have a life expectancy of at least 12 weeks, measurable disease, and be willing to follow birth control guidelines. People can't join if they're pregnant, breastfeeding, recently used certain cancer drugs or immunotherapies, had organ transplants, active autoimmune diseases, or stem cell transplantation within the last 100 days.Inclusion Criteria
I agree to provide tissue samples for the study.
I have relapsed/refractory multiple myeloma and cannot tolerate or have no other standard treatments left.
I have been diagnosed with Multiple Myeloma.
See 5 more
Exclusion Criteria
I haven't taken any antibody treatments for my MM in the last 2 weeks.
I haven't taken any immune system treatments in the last 2 weeks.
I had a stem cell transplant within the last 100 days or have ongoing signs of graft versus host disease.
See 7 more
Treatment Details
Interventions
- RO7425781 (Monoclonal Antibodies)
Trial OverviewThe study tests escalating doses of Forimtamig in two parts: first finding the right dose (Part 1) and then giving that dose to more people to see how well it works (Part 2). It's for patients with no standard treatment options left or those intolerant to existing therapies.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Part II: Dose ExpansionExperimental Treatment1 Intervention
Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase.
Group II: Part I: Dose EscalationExperimental Treatment1 Intervention
Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University